Pharmacosmos initiates phase III clinical trial of trilaciclib in limited-stage small cell lung cancer MORRISTOWN, NJ, ...
One year ago, Louisiana broke a fifteen-year silence on executions by debuting nitrogen hypoxia. Officials called Jessie Hoffman Jr.’s death “flawless,” yet their own reports noted “convulsive ...
Niagen Bioscience Secures New U.S. Patent Covering Intravenous and Injection Formulations and Methods of Use for Nicotinamide Riboside (NR), Niagen® Patent strengthens Niagen Bioscience’s intellectual ...
Patent strengthens Niagen Bioscience’s intellectual property moat in fast-growing NAD+-boosting IV and injectable delivery formats, supporting commercial expansion and deterring infringers Under its ...
Patent strengthens Niagen Bioscience’s intellectual property moat in fast-growing NAD+-boosting IV and injectable delivery formats, supporting commercial expansion and deterring infringers LOS ANGELES ...
Rob Fried, CEO of Niagen Bioscience, commented, “This patent expands our intellectual property for our patented NR ingredient, Niagen ®, into IV and injectable delivery formats. With expected ...
With Hillary Clinton more than 300,000 votes ahead of President-elect Donald Trump in the popular vote count as of Thursday, calls have already begun to ditch the Electoral College system enshrined in ...
Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...
Objectives: to construct and verify the clinical applicability of a flowchart for assessing children and adolescents who will undergo peripheral intravenous catheterization, according to risk factors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results